CytomX Therapeutics (CTMX) Cash from Investing Activities Growth (3y) (2017 - 2026)
CytomX Therapeutics (CTMX) Cash from Investing Activities Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -29.84% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 38.24% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -22.09% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | CytomX Therapeutics | 582.34 Mn | 235.63 Mn | - | -9.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.55% |
| Dec 31, 2025 | -28.96% |
| Sep 30, 2025 | 45.35% |
| Jun 30, 2025 | -470.15% |
| Mar 31, 2025 | 251.88% |
| Dec 31, 2024 | 299.53% |
| Sep 30, 2024 | 23.12% |
| Jun 30, 2024 | 35.13% |
| Mar 31, 2024 | -8.72% |
| Dec 31, 2023 | -12.88% |
| Sep 30, 2023 | 21.88% |
| Jun 30, 2023 | -19.25% |
| Mar 31, 2023 | -295.95% |
| Dec 31, 2022 | 23.60% |
| Sep 30, 2022 | -26.22% |
| Jun 30, 2022 | -27.23% |
| Mar 31, 2022 | 65.93% |
| Dec 31, 2021 | -26.32% |
| Sep 30, 2021 | 71.69% |
| Jun 30, 2021 | -68.26% |